Cystic Fibrosis Trial Endpoints May Be Revised Following FDA Workshop
This article was originally published in The Pink Sheet Daily
Executive Summary
Quality-of-life metrics deserve consideration in addition to lung function in the development of aerosolized antimicrobials, researchers say.
You may also be interested in...
Cystic Fibrosis Trials: CDER Officials Disagree Over Value Of FEV1 Endpoint
There is an apparent split within FDA's Center for Drug Evaluation and Research on the usefulness of measuring the amount of air a patient can blow in one second as a primary outcome measure in trials of aerosolized antimicrobial drugs for cystic fibrosis.
Cystic Fibrosis Trials: CDER Officials Disagree Over Value Of FEV1 Endpoint
There is an apparent split within FDA's Center for Drug Evaluation and Research on the usefulness of measuring the amount of air a patient can blow in one second as a primary outcome measure in trials of aerosolized antimicrobial drugs for cystic fibrosis.
FDA Cites Clinical Investigator In Six Trials Of Three Cystic Fibrosis Drugs
FDA's oversight of clinical trials is becoming an increasingly significant factor in regulatory delays for some products, and a recent warning letter could have a very broad impact: it cites a clinical investigator for six trials related to three separate NDAs